NEW YORK CITY, New York: At the start of 2025, drug companies raised prices on over 250 brand-name medications in the U.S., including Pfizer's COVID-19 treatment Paxlovid, Bristol Myers Squibb's ...
More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
Ibrance is under clinical development by Pfizer and currently in Phase II for Metastatic Brain Tumor. According to GlobalData, Phase II drugs for Metastatic Brain Tumor have a 20% phase transition ...
INR:9831. slots bingo online Results announced! Abbott made so much in three months AstraZeneca's COVID-19 vaccine is approved for emergency supply in the UK!
INR:1237. is there horse racing in ireland today Phase III clinical trial approval: new progress of Hengrui's blockbuster ...
Ganlai's FXR agonist ASC42 completes first patient dosing in US Phase I clinical trial Novartis' Kisqal is superior to Pfizer's Ibrance in metastatic breast cancer, with a median survival of 5 years N ...
The key protein for repairing nerve fibers has been "captured" Pfizer 2020 performance: Ibrance lost in adjuvant treatment of ...
The medicines are: Pharmac is also consulting on a price reduction and brand change for palbociclib used for advanced breast cancer, from Ibrance to Palbociclib Pfizer (supplied by the same supplier).
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to standard anti-HER2 and endocrine therapy may become a new standard of care for frontline maintenance treatment of hormone ...